[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/29, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 [ESMO] AZ, 방광암 '임핀지+파드셉' 3상 성공.."新이슈 촉발" 
[https://www.biospectator.com/news/view/30220](https://www.biospectator.com/news/view/30220)

 [ESMO] 지아이이노, 'CD80/IL-2v' SC제형 1상 "ESMO IO 발표"
[https://www.biospectator.com/news/view/30229](https://www.biospectator.com/news/view/30229)

 [ESMO] BMS-바이오엔텍, 'PD-L1xVEGF' 폐암 2상 "잠재력”
[https://www.biospectator.com/news/view/30200](https://www.biospectator.com/news/view/30200)

 SK바사, IAVI·힐레만硏와 美지원 '에볼라백신' 개발협력
[https://www.biospectator.com/news/view/30233](https://www.biospectator.com/news/view/30233)

 ‘KRAS 변이’ 치료제 “개발한계와 앞으로 방향 4가지는?”
[https://www.biospectator.com/news/view/30098](https://www.biospectator.com/news/view/30098)

 [ESMO] 릴리, 'FRα ADC' 백금민감성 난소암 1상 "ORR 79%" 
[https://www.biospectator.com/news/view/30226](https://www.biospectator.com/news/view/30226)

 [ESMO] GSK, B7-H3 ADC '약물없는' 골육종 3상 "PFS 67%↑"
[https://www.biospectator.com/news/view/30221](https://www.biospectator.com/news/view/30221)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/29, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)